

REFERENCES:

Natural Pharmacy Business Magazine – August/September 2022

Pg12-14 – Joints and Bones CPD

1. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. *Ann Rheum Dis*. 2019;78:1463-1471.
2. Wallace IJ, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. *Proc Natl Acad Sci U S A*. 2017 Aug 29; 114(35):9332-36.
3. Neogi T, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. *Arthritis Rheum*. 2006 Apr;54(4):1255-61.
4. Koshihara Y, Hoshi K, Shiraki M. Vitamin K2 (menatetrone) inhibits prostaglandin synthesis in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity. *Biochem Pharmacol*. 1993 Oct 19;46(8):1355-62.
5. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. *J Biol Chem*. 2006;281(25):16927-16934. doi:10.1074/jbc.M600896200
6. Sato T. Vitamin K2 and Bone Quality. *Vitam. Trace Elem*. 2012:S6. doi: 10.4172/2167-0390.S6-001
7. Chin KY. The Relationship between Vitamin K and Osteoarthritis: A Review of Current Evidence. *Nutrients*. 2020 May; 12(5): 1208.
8. van Summeren M, Braam L, Noirt F, Kuis W, Vermeer C. Pronounced elevation of undercarboxylated osteocalcin in healthy children. *Pediatr Res*. 2007 Mar;61(3):366-70
9. O'Connor E, Mølgaard C, Michaelsen KF, Jakobsen J, Lamberg-Allardt CJ, Cashman KD. Serum percentage undercarboxylated osteocalcin, a sensitive measure of vitamin K status, and its relationship to bone health indices in Danish girls. *Br J Nutr*. 2007 Apr;97(4):661-6.
10. Kalkwarf HJ, Khoury JC, Bean J, Elliot JG. Vitamin K, bone turnover, and bone mass in girls. *Am J Clin Nutr*. 2004 Oct;80(4):1075-80.
11. Khosla S, Melton LJ 3rd, Dekutoski MB, Achenbach SJ, Oberg AL, Riggs BL. Incidence of childhood distal forearm fractures over 30 years: a population-based study. *JAMA*. 2003 Sep 17;290(11):1479-85.
12. Szmodis M, Bosnyák E, Protzner A, Szots G, Trájer E, Tóth M. Relationship between physical activity, dietary intake and bone parameters in 10-12 years old Hungarian boys and girls. *Cent Eur J Public Health*. 2019 Mar;27(1):10-16. doi: 10.21101/cejph.a5140.
13. Karpinski M, Popko J, Maresz K, Badmaev V, Stohs SJ. Roles of Vitamins D and K, Nutrition, and Lifestyle in Low-Energy Bone Fractures in Children and Young Adults. *J Am Coll Nutr*. 2017;36(5):399-412.
14. Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, Binnekamp IA, van Summeren MJ, Vermeer C. Vitamin K status in healthy volunteers. *Food Funct*. 2014 Feb;5(2):229-34.

15. Popko J, Karpinski M, Chojnowska S, Maresz K, Milewski R, Badmaev V, Schurgers LJ. Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study. *Nutrients*. 2018 Jun 6;10(6).
16. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res*. 2000;15:515-21.
17. Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. *Maturitas*. 1999;31:161-4.
18. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. *Calcif Tissue Int*. 2000;66:123-8.
19. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. *Osteoporos Int*. 2007;18(7):963-972.
20. Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures. systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med*. 2006;166:1256-61.
21. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. *Osteoporos Int*. 2013 Sep;24(9):2499-507.
22. Ozdemir MA, Yilmaz K, Abdulrezzak U, Muhtaroglu S, Patiroglu T, Karakukcu M, Unal E. The efficacy of vitamin K2 and calcitriol combination on thalassemic osteopathy. *J Pediatr Hematol Oncol*. 2013 Nov;35(8):623-7.
23. van Summeren MJ, Braam LA, Lilien MR, Schurgers LJ, Kuis W, Vermeer C. The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children. *Br J Nutr*. 2009 Oct;102(8):1171-8.
24. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res*. 2000;15:515-21.
25. Iwamoto I, Kosha S, Noguchi S, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy. *Maturitas*. 1999;31:161-4.
26. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. *Osteoporos Int*. 2007 Jul; 18(7):963-72.
27. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. *Osteoporos Int*. 2013 Sep; 24(9):2499-507.
28. Sato T, Inaba N, Yamashita T. MK-7 and Its Effects on Bone Quality and Strength. *Nutrients*. 2020;12(4):965. Published 2020 Mar 31. doi:10.3390/nu12040965
29. Neogi T, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. *Arthritis Rheum*. 2006 Apr;54(4):1255-61.
30. Abdel-Rahman MS, et al. Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study. *Eur J Pharmacol*. 2015 Aug 15;761:273-8. doi: 10.1016/j.ejphar.2015.06.014. Epub 2015 Jun 11.
31. Ebina K, Shi K, Hirao M, et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. *Mod Rheumatol*. 2013;23(5):1001-1007. doi:10.1007/s10165-012-0789-4
32. Ganguly A. Role of Jumpstart Nutrition®, a Dietary Supplement, to Ameliorate Calcium-to-Phosphorus Ratio and Parathyroid Hormone of Patients with Osteoarthritis. *Med Sci (Basel)*. 2019;7(12):105. Published 2019 Nov 22. doi:10.3390/medsci7120105
33. Ishii Y, Noguchi H, Takeda M, et al. Distribution of vitamin K2 in subchondral bone in osteoarthritic knee joints. *Knee Surg Sports Traumatol Arthrosc*. 2013;21(8):1813-1818. doi:10.1007/s00167-012-2239-4

Pg20-22 – IBS

1. Irritable bowel syndrome in adults: diagnosis and management | Guidance and guidelines | NICE.
2. Arzani M, Jahromi SR, Ghorbani Z, et al. Gut-brain Axis and migraine headache: A comprehensive review. *J Headache Pain*. 2020;21(1). doi:10.1186/s10194-020-1078-9
3. Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. *Gastroenterology*. 2016;150(6). doi:10.1053/j.gastro.2016.02.032
4. Harper A, Naghibi M, Garcha D. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. *Foods*. 2018;7(2):13. doi:10.3390/foods7020013
5. Young VB. The role of the microbiome in human health and disease: An introduction for clinicians. *BMJ*. 2017;356. doi:10.1136/bmj.j831
6. Jalanka-Tuovinen J, Salonen A, Nikkilä J, et al. Intestinal microbiota in healthy adults: Temporal analysis reveals individual and common core and relation to intestinal symptoms. *PLoS One*. 2011;6(7). doi:10.1371/journal.pone.0023035
7. Mari A, Abu Baker F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. *J Clin Med*. 2020;9(3). doi:10.3390/jcm9030685
8. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010;464(7285):59-65. doi:10.1038/nature08821
9. Weiss GA, Henet T. Mechanisms and consequences of intestinal dysbiosis. *Cell Mol Life Sci*. 2017;74(16). doi:10.1007/s00018-017-2509-x
10. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). *Eur J Gastroenterol Hepatol*. 1998;10(1):59-62.
11. Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science (80-)*. 2016;352(6285):565-569. doi:10.1126/science.aad3369
12. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? *World J Gastroenterol*. 2014;20(39):14105-14125. doi:10.3748/wjg.v20.i39.14105
13. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery. *Gastroenterology*. 2006;131(2):445-450. doi:10.1053/j.gastro.2006.05.053
14. Wang L, Alammari N, Singh R, et al. Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. *J Acad Nutr Diet*. 2020;120(4). doi:10.1016/j.jand.2019.05.015
15. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. *Nutrients*. 2013;5(6):1869-1912. doi:10.3390/nu5061869
16. Tejero-Sariñena S, Barlow J, Costabile A, Gibson GR, Rowland I. In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: Evidence for the effects of organic acids. *Anaerobe*. 2012;18(5):530-538. doi:10.1016/j.anaerobe.2012.08.004
17. Simon E, Călinoiu LF, Mitrea L, Vodnar DC. Probiotics, prebiotics, and synbiotics: Implications and beneficial effects against irritable bowel syndrome. *Nutrients*. 2021;13(6). doi:10.3390/nu13062112
18. Klein A, Friedrich U, Vogelsang H, Jahreis G. *Lactobacillus acidophilus* 74-2 and *Bifidobacterium animalis* subsp *lactis* DGCC 420 modulate unspecific cellular immune response in healthy adults. *Eur J Clin Nutr*. 2008;62(5):584-593. doi:10.1038/sj.ejcn.1602761

19. Dogi CA, Weill F, Perdigón G. Immune response of non-pathogenic Gram(+) and Gram(-) bacteria in inductive sites of the intestinal mucosa. Study of the pathway of signaling involved. *Immunobiology*. 2010;215(1):60-69. doi:10.1016/j.imbio.2009.01.005
 20. Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, De los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. *Front Microbiol*. 2016;7(FEB). doi:10.3389/fmicb.2016.00185
 21. Park J, Kim M, Kang SG, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. *Mucosal Immunol*. 2015;8(1):80-93. doi:10.1038/mi.2014.44
 22. Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(10):1547-1562. doi:10.1038/ajg.2014.202
 23. Didari T. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol*. 2015;21(10):3072. doi:10.3748/wjg.v21.i10.3072
 24. Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in irritable bowel syndrome: An up-to-date systematic review. *Nutrients*. Published online 2019. doi:10.3390/nu11092048
 25. McKenzie YA, Thompson J, Gulia P, Lomer MCE. British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). *J Hum Nutr Diet*. 2016;29(5):576-592. doi:10.1111/jhn.12386
 26. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. *BMC Gastroenterol*. 2018;18(1). doi:10.1186/s12876-018-0788-9
-